Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
Radboud Univ Nijmegen, Med Ctr, Radboudumc Ctr Infect Dis, TB Expert Ctr Dekkerswald,Dept Pulm Dis, Nijmegen, Netherlands..
Univ Florida, Ctr Pharmacometr & Syst Pharmacol, Dept Pharmaceut, Gainesville, FL USA.;Univ Maiduguri, Coll Med Sci, Fac Basic Clin Sci, Dept Clin Pharmacol & Therapeut, Maiduguri, Nigeria.;Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Div Clin Pharmacol, Cape Town, South Africa..
Radboud Univ Nijmegen, Med Ctr, Radboudumc Ctr Infect Dis, Radboud Inst Hlth Sci,Dept Pharm, Nijmegen, Netherlands..
Radboud Univ Nijmegen, Med Ctr, Radboudumc Ctr Infect Dis, Dept Med Microbiol, Nijmegen, Netherlands..ORCID iD: 0000-0002-0581-2003
Show others and affiliations
2023 (English)In: Respiration, ISSN 0025-7931, E-ISSN 1423-0356, Vol. 102, no 2, p. 83-100Article, review/survey (Refereed) Published
Abstract [en]

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6 months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK), emergence of drug resistance, presence of comorbidities, and adverse drug reactions complicate TB therapy and drive the need for new drugs and/or regimens. Hence, new compounds are being developed, available drugs are repurposed, and the dosing of existing drugs is optimized, resulting in the largest drug development portfolio in TB history. This review highlights a selection of clinically available drug candidates that could be part of future TB regimens, including bedaquiline, delamanid, pretomanid, linezolid, clofazimine, optimized (high dose) rifampicin, rifapentine, and para-aminosalicylic acid. The review covers drug development history, preclinical data, PK, and current clinical development.

Place, publisher, year, edition, pages
S. Karger, 2023. Vol. 102, no 2, p. 83-100
Keywords [en]
Drugs, Treatment, Tuberculosis
National Category
Pharmaceutical Sciences Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-502447DOI: 10.1159/000528274ISI: 000897216300001PubMedID: 36516792OAI: oai:DiVA.org:uu-502447DiVA, id: diva2:1759395
Available from: 2023-05-25 Created: 2023-05-25 Last updated: 2023-05-25Bibliographically approved

Open Access in DiVA

fulltext(671 kB)154 downloads
File information
File name FULLTEXT01.pdfFile size 671 kBChecksum SHA-512
1282760298ec9333c846a4d3a7a0bb9cb075417612fa4ee358cc3c4813a8e52a7c9a804018291536c3c7903c50dc9fe7c9cea4f62538f80030efc1d0c801500d
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Svensson, Elin

Search in DiVA

By author/editor
van Ingen, JakkoRaaijmakers, JelmerSvensson, Elin
By organisation
Department of Pharmacy
In the same journal
Respiration
Pharmaceutical SciencesPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 155 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 151 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf